Stromal PD‐1/PD‐L1 Expression Predicts Outcome in Colon Cancer Patients

[1]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[2]  H. Lenz,et al.  Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[4]  L. Ni,et al.  New B7 Family Checkpoints in Human Cancers , 2017, Molecular Cancer Therapeutics.

[5]  Phil Quirke,et al.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016 , 2017, Modern Pathology.

[6]  Mingfeng Zhang,et al.  PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells , 2017, The Journal of clinical investigation.

[7]  T. Fujii,et al.  Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer , 2017, Cancer science.

[8]  Soyeon Ahn,et al.  Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer , 2017, Cancer Immunology, Immunotherapy.

[9]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[10]  D. Rimm,et al.  A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1 , 2017, JAMA oncology.

[11]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[12]  M. Seto,et al.  PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. , 2016, Blood.

[13]  A. Barzi,et al.  Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012 , 2016, Oncotarget.

[14]  Mari Mino-Kenudson,et al.  PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes , 2016, Modern Pathology.

[15]  Mingyang Song,et al.  Tumour CD274 (PD-L1) expression and T cells in colorectal cancer , 2016, Gut.

[16]  H. Lenz,et al.  The safety of monoclonal antibodies for treatment of colorectal cancer , 2016, Expert opinion on drug safety.

[17]  Z. Trajanoski,et al.  Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.

[18]  T. Cotechini,et al.  Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis , 2016, Oncotarget.

[19]  Ahmedin Jemal,et al.  Global patterns and trends in colorectal cancer incidence and mortality , 2016, Gut.

[20]  Toby C. Cornish,et al.  Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma , 2016, Gut.

[21]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[22]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[23]  Xue Han,et al.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.

[24]  E. Wardelmann,et al.  PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups , 2015, PloS one.

[25]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[26]  Jian Huang,et al.  PD-L1 and Survival in Solid Tumors: A Meta-Analysis , 2015, PloS one.

[27]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[28]  G. Freeman,et al.  Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma , 2015, Cancer Immunology Research.

[29]  J. Madore,et al.  PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials , 2015, Pigment cell & melanoma research.

[30]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.

[31]  I. Zlobec,et al.  A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies , 2014, Journal of visualized experiments : JoVE.

[32]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[33]  D. Hua,et al.  MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. , 2014, Human immunology.

[34]  M. Borner,et al.  CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival , 2014, Journal of Translational Medicine.

[35]  Li-juan Wang,et al.  B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells , 2013, PloS one.

[36]  Shaohua Chen,et al.  The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies , 2013, Journal of Hematology & Oncology.

[37]  L. Terracciano,et al.  Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. , 2013, European journal of cancer.

[38]  J. Taube,et al.  Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. , 2013, Cancer research.

[39]  J. Hecht,et al.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.

[40]  L. Zitvogel,et al.  Targeting PD-1/PD-L1 interactions for cancer immunotherapy , 2012, Oncoimmunology.

[41]  Haidong Dong,et al.  B7-H1 Expressed by Activated CD8 T Cells Is Essential for Their Survival , 2011, The Journal of Immunology.

[42]  N. Petrelli,et al.  Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  S. McSorley,et al.  B7-H1 (Programmed Cell Death Ligand 1) Is Required for the Development of Multifunctional Th1 Cells and Immunity to Primary, but Not Secondary, Salmonella Infection , 2010, The Journal of Immunology.

[44]  S. Qiu,et al.  Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[45]  S. Boorjian,et al.  T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival , 2008, Clinical Cancer Research.

[46]  Lieping Chen,et al.  Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.

[47]  K. Okumura,et al.  Blockade of B7-H1 on Macrophages Suppresses CD4+ T Cell Proliferation by Augmenting IFN-γ-Induced Nitric Oxide Production1 , 2005, The Journal of Immunology.

[48]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[49]  G. Zhu,et al.  B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. , 2001, Blood.

[50]  S. Dzik.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .

[51]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.